Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Sydney-based companion diagnostic and personalized medicine company Clarity has appointed Alan Taylor as its new executive chairman to the board. 19 December 2013
German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined the company as director of business operations. 16 December 2013
New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate. 16 December 2013
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided inspiration to UK life science companies at the Genesis 2013 conference. 16 December 2013
Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were revealed at the Genesis 2013 conference in London on Thursday. 16 December 2013
Israel’s Teva Pharmaceutical Industries announced yesterday that the vice chairman of its board of directors, Moshe Many, has requested to leave his position effective January 1, 2014. Prof Many will remain a member of Teva's Board. 11 December 2013
Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected at its AGM on March 4, 2014. The board proposes Christoph Franz to be elected as Chairman of the Board. 10 December 2013
Denmark-based small molecule lead discovery company Nuevolution A/S has appointed Ton Berkien as Chief Business Officer from January 1. 9 December 2013
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member. 9 December 2013
The France-based biotechnology company Novasep has announced Nadege Laborde as the new president of its industrial biotech business unit. 6 December 2013
Eyal Desheh, acting president and chief executive of the world’s largest generics maker Teva (NYSE: TEVA), told delegates at the Financial Times Global Pharmaceutical & Biotechnology Conference in London yesterday that the company is “prepared” for the patent loss of Copaxone (glatiramer acetate) next year. 5 December 2013
A Twitter debate was sparked yesterday after the Financial Times Global Pharmaceutical & Biotechnology Conference questioned its audience about the gaps in the industry’s skills base. 4 December 2013
The chair of the UK’s regulatory body the National Institute for Health and Care Excellence shared his view of the drug approvals process at the Financial Times Global Pharmaceutical & Biotechnology Conference in London yesterday. 4 December 2013
Most patients don’t appreciate the pharma companies that save their lives, Bayer chairman Marijn Dekkers told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013